The RESTORE-1 study for Atrial Fibrillation (AF) is actively recruiting patients diagnosed with AF for participation. You can access study related information and find a participating hospital near you at:
restore-1study.com/us-en
We want to welcome Robert Lisicki to the InCarda Therapeutics family as our new CEO and Board Member.
And, we want to thank Grace Colón for nearly a decade of dedication to InCarda and patients living with atrial fibrillation.
tinyurl.com/5b6ujwem
This #HispanicHeritageMonth, we recognize Grace E. Colón. @ColonGraceE, the President and Chief Executive Officer of InCarda Therapeutics, Inc. who brings years of experience in biopharma, genomics, healthcare, and industrial biotechnology. bit.ly/3qp2URm
Today marks the start of National Atrial Fibrillation Awareness Month.
At InCarda, we are driven by our desire to help empower patients living with AFib to have more control over their disease.
#afibmonth22#EPeeps#stopafib#afib
Another awesome patient conference from @stopafib in the books! Very informative content presented by world-class providers. Some highlights: treatment options for AF, importance of rhythm control and the role of health tech in AF and drug monitoring.
#stopafib22#epeeps
We are excited to share that the first patient has been enrolled into our Phase 3 RESTORE-1 pivotal study. A huge milestone for InCarda and for patients with atrial fibrillation that we hope to serve!
lnkd.in/euhcKQDE#innovative#EPeeps
We are so enjoying #HRS2022 here in our backyard of San Francisco! We hope all our #EPeeps are too. In case you missed it today, we were very excited to present results of our INSTANT P2 study!